Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
The identification of the PD-1 receptor by Tasuku Honjo and CTLA-4 by James Ellison marked the beginning of the study of new regulatory pathways activating the immune response. The term “immune checkpoints” was introduced to denote the system of inhibitory mechanisms that include these proteins. The...
Enregistré dans:
Auteurs principaux: | A. V. Chetveryakov, V. L. Tsepelev |
---|---|
Format: | article |
Langue: | RU |
Publié: |
Scientific Сentre for Family Health and Human Reproduction Problems
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/ea6c4a1bb2ae4dbe9e16de4c96530ab5 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
par: I. O. Chikileva, et autres
Publié: (2019) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
par: Utpal Kumar, et autres
Publié: (2021) -
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
par: Xin Cai, et autres
Publié: (2021) -
The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer
par: Yaping Chen, et autres
Publié: (2021) -
Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
par: Kimberly M. Burcher, et autres
Publié: (2021)